Canada pharma trade group says patients to be worse affected by PMPRB amendments

10 August 2019

Innovative Medicines Canada (IMC) warns that the amendments to the Patented Medicine Prices Review Board’s (PMPRB) Regulations announced Friday will limit Canadian patients’ access to new innovative medicines and discourage investment in Canada’s life sciences sector for years to come.

“We have just received the amended Regulations and will require time to analyze them fully,” stated Pamela Fralick, president of IMC, adding: “However, given what we have heard to date, our fear is that patients will be worse off.”

The PMPRB’s own case studies indicate the amended Regulations will drop drug ceiling prices by up to 70%, severely weakening the business case to launch new medicines in Canada. A recent EY study confirms that there is indeed a correlation between market conditions when it comes to global drug launch decisions, contrary to Health Canada’ statements, the trade group points out.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK